IsoPlexis is a biotechnology company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond.
IsoPlexis' Award-Winning Single-Cell System uniquely reveals the most potent functional cell subsets that secrete multiple cytokines simultaneously at high intensity.
IsoPlexis was founded in 2013 by Sean Mackay and Kara Brower. The company is headquartered in Branford, Connecticut.
IsoPlexis is accelerating the fight against our toughest diseases by revealing the true functional biology of every patient cell.
IsoPlexis is dedicated to accelerating the fight against cancer and a range of the world’s toughest diseases with our uniquely correlative, award-winning single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, it is advancing immunotherapies and targeted therapies to a more highly precise & personalized stage.
IsoPlexis' integrated systems, named #1 innovation by the Scientist Magazine & Fierce, are used globally to advance the field of single-cell biology and biomarkers as we generate solutions to overcome the challenges of complex diseases.
IsoPlexis is backed by Northpond Ventures, Spring Mountain Capital, Ironwood Capital, North Sound Capital, Connecticut Innovations, and others. The company raised an additional $20 million in its Series C financing on Jan 09, 2020, bringing the entire Series C round to $45M. The lates financing brings the total funding raised by IsoPlexis to $66.2M to date.